BMI Requirements for Ozempic, Wegovy, and Mounjaro — FDA Guidelines

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed weight management treatment. Eligibility for these medications is based primarily on BMI, with and without qualifying comorbidities. Knowing your BMI is the first step to understanding whether you might qualify.

Use the free BMI calculator to calculate your current BMI. This guide explains how that number maps to FDA approval criteria for each medication.

Important: This information is educational, not medical advice. Prescribing decisions are made by licensed healthcare providers who consider your full medical history, contraindications, and clinical judgment. A qualifying BMI does not guarantee a prescription.

FDA Approval Criteria — BMI Thresholds

Medication	Brand (Indication)	BMI ≥30	BMI ≥27 with Comorbidity
Semaglutide 2.4mg	Wegovy (weight management)	✓ Approved	✓ Approved
Semaglutide 0.5-2mg	Ozempic (diabetes only)	For type 2 diabetes, not weight alone	For type 2 diabetes, not weight alone
Tirzepatide (injection)	Zepbound (weight management)	✓ Approved	✓ Approved
Tirzepatide (injection)	Mounjaro (diabetes)	For type 2 diabetes	For type 2 diabetes
Liraglutide 3mg	Saxenda (weight management)	✓ Approved	✓ Approved

The important distinction: Ozempic and Mounjaro are FDA-approved for type 2 diabetes management. Many doctors prescribe them off-label for weight loss in non-diabetic patients with qualifying BMI, but the on-label indication is diabetes. Wegovy (same drug as Ozempic, higher dose) and Zepbound (same drug as Mounjaro, different dosing) are specifically approved for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity.

Qualifying Comorbidities for the BMI 27+ Threshold

At BMI 27-29.9, these medications require at least one weight-related comorbidity for on-label approval:

• Type 2 diabetes or prediabetes
• High blood pressure (hypertension) — diagnosed and being managed
• Dyslipidemia — elevated LDL cholesterol or triglycerides
• Obstructive sleep apnea — diagnosed with sleep study
• Cardiovascular disease — prior heart attack, stroke, or established atherosclerosis (for Wegovy specifically, this is explicitly included)

"Weight-related" is important — these must be conditions that excess body weight contributes to or worsens. A condition like kidney disease or hypothyroidism alone would not typically qualify as the weight-related comorbidity unless the provider can establish a clear weight-related component.

Sell Custom Apparel — We Handle Printing & Free Shipping

How to Use Your BMI to Check Potential Eligibility

This is a two-step check:

Step 1: Calculate your BMI using the free BMI calculator. Enter your current weight and height.

Step 2: Apply the criteria:

• BMI ≥30: You meet the BMI threshold for Wegovy and Zepbound without needing a qualifying comorbidity
• BMI 27–29.9: You meet the threshold if you also have at least one qualifying comorbidity (see list above)
• BMI under 27: You do not currently meet the on-label weight management criteria for these medications. Off-label prescribing is at physician discretion but is less common and often not covered by insurance below this threshold.

Insurance coverage adds another layer — even with a qualifying BMI, many insurance plans require prior authorization, specific diagnosis codes, documented failure of lifestyle interventions, and sometimes a minimum duration of obesity diagnosis before approving coverage.

Other Factors That Affect Whether You Get Prescribed These Medications

A qualifying BMI is necessary but not sufficient. Your provider will also consider:

• Contraindications: Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis history, or severe gastrointestinal disease may contraindicate GLP-1 medications
• Pregnancy: These medications are contraindicated in pregnancy and require stopping well before conception attempts
• Prior treatment history: Many insurance policies require documented lifestyle intervention (diet and exercise counseling) for a specified period before approving weight management medications
• Current medications: Potential drug interactions, especially with diabetes medications, require careful review
• Insurance and cost: Monthly costs without insurance can be $900-$1,500+. Insurance coverage varies significantly by plan

The most direct path: calculate your BMI, note whether you have qualifying comorbidities, and schedule an appointment with your primary care provider or an obesity medicine specialist to discuss your options.

Frequently Asked Questions

What BMI do you need for Ozempic?

Ozempic (semaglutide 0.5-2mg) is FDA-approved for type 2 diabetes — not primarily for weight loss. For weight management, Wegovy (same drug, higher dose at 2.4mg) is the approved version, requiring BMI ≥30 or BMI ≥27 with at least one qualifying comorbidity. Off-label prescribing of Ozempic for weight loss in non-diabetic patients with qualifying BMI does occur but varies by physician and insurance coverage.

What BMI qualifies for Wegovy?

Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management in adults with BMI ≥30 (obese), or BMI ≥27 (overweight) with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea. Calculate your BMI with a free online tool to see whether you meet the threshold.

Can I get Mounjaro for weight loss?

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Zepbound — the same drug marketed specifically for weight management — is FDA-approved for BMI ≥30 or ≥27 with comorbidity, same as Wegovy. Off-label prescribing of Mounjaro for weight loss occurs, but Zepbound is the on-label weight management option. Coverage and prescribing practices vary by insurance plan and provider.